Intercellular nanotube-mediated mitochondrial transfer enhances T cell metabolic fitness and antitumor efficacy.

Mitochondrial loss and dysfunction drive T cell exhaustion, representing major barriers to successful T cell-based immunotherapies. Here, we describe an innovative platform to supply exogenous mitochondria to T cells, overcoming these limitations. We found that bone marrow stromal cells establish nanotubular connections with T cells and leverage these intercellular highways to transplant stromal cell mitochondria into CD8

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests J.G.B., T.S., J.F., S.S., and L.G. have a patent application for the use of mitochondrial transfer technology in cancer immunotherapies. P.B. and S.G. have an employee relationship and have stock in AstraZeneca. B.W.H. has an employee relationship and has stock in Genmab. L.G. has consulting agreements with Lyell Immunopharma, Instil Bio, and Advaxis. L.G. is on the scientific advisory board of Poseida Therapeutics and Kiromic and a stockholder of Poseida Therapeutics. M.I. participates in advisory boards/consultancies for Gilead Sciences, Third Rock Ventures, Antios Therapeutics, Asher Biotherapeutics, GentiBio, Clexio Biosciences, Sybilla, and BlueJay Therapeutics. J.F. has an employee relationship and has stock in Lyell Immunopharma. S.S. is a founder and owns equity in Vyome Therapeutics Inc. and Alyssum Therapeutics Inc.